ES2002490A6 - Un metodo de preparar un virus recombinante - Google Patents

Un metodo de preparar un virus recombinante

Info

Publication number
ES2002490A6
ES2002490A6 ES8602123A ES8602123A ES2002490A6 ES 2002490 A6 ES2002490 A6 ES 2002490A6 ES 8602123 A ES8602123 A ES 8602123A ES 8602123 A ES8602123 A ES 8602123A ES 2002490 A6 ES2002490 A6 ES 2002490A6
Authority
ES
Spain
Prior art keywords
virus
preparing
lav
htlv
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8602123A
Other languages
English (en)
Spanish (es)
Inventor
Shiu-Lok Hu
Anthony F Purchio
Linda Madisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of ES2002490A6 publication Critical patent/ES2002490A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES8602123A 1985-09-25 1986-09-24 Un metodo de preparar un virus recombinante Expired ES2002490A6 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (1)

Publication Number Publication Date
ES2002490A6 true ES2002490A6 (es) 1988-08-16

Family

ID=27419757

Family Applications (2)

Application Number Title Priority Date Filing Date
ES8602123A Expired ES2002490A6 (es) 1985-09-25 1986-09-24 Un metodo de preparar un virus recombinante
ES8801494A Expired ES2006941A6 (es) 1985-09-25 1988-05-13 Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii).

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES8801494A Expired ES2006941A6 (es) 1985-09-25 1988-05-13 Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii).

Country Status (22)

Country Link
CN (1) CN1020752C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATA256786A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH676247A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3690508T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK455486A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2002490A6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI863848A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2587720A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2181435B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR862412B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU205780B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE59314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL80073A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1195829B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY103182A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8602422A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO863803L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ217645A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT83434B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (4) SE8604007L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1987002038A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU46753B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109512T1 (de) * 1985-04-08 1994-08-15 Genetic Systems Corp Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
DE3750151T2 (de) * 1986-09-19 1994-12-01 Oncogen Verwendung von aktivierten T-Lymphozyten zur Vorbereitung einer pharmazeutischen Zusammensetzung zur Behandlung von AIDS.
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
EP0272858A3 (en) * 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ATE110112T1 (de) * 1988-05-06 1994-09-15 Ferropas Ag Verfahren und systeme zur herstellung von hiv- antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
WO1990015141A2 (en) * 1989-06-01 1990-12-13 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
ES2177530T3 (es) * 1991-11-08 2002-12-16 Upjohn Co Vacunas contra el virus de la leucemia felina.
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
AU5259796A (en) * 1995-02-10 1996-08-27 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ATE188783T1 (de) * 1995-09-06 2000-01-15 Schablonentechnik Kufstein Ag Verfahren zum herstellen einer siebdruckschablone
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1458360T3 (da) 2001-12-19 2011-08-29 Novartis Ag Pulmonær afgivelse af aminoglycosider

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58011B1 (en) * 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
ES8705522A1 (es) * 1984-10-18 1987-05-01 Pasteur Institut Un procedimiento para la preparacion de derivados purificados de una glicoproteina.
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
DE3588134T2 (de) * 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
FI861626A7 (fi) * 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Also Published As

Publication number Publication date
NO863803L (no) 1987-03-26
GB8622987D0 (en) 1986-10-29
SE8604007D0 (sv) 1986-09-23
GR862412B (en) 1987-01-23
YU165486A (en) 1989-08-31
DK455486A (da) 1987-03-26
IE59314B1 (en) 1994-02-09
SE9102974D0 (sv) 1991-10-14
MY103182A (en) 1993-05-29
FI863848L (fi) 1987-03-26
SE8604007L (sv) 1987-03-26
NZ217645A (en) 1991-11-26
SE9102976L (sv) 1993-04-15
HU205780B (en) 1992-06-29
FR2587720A2 (fr) 1987-03-27
GB2181435A (en) 1987-04-23
CH676247A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-12-28
ES2006941A6 (es) 1989-05-16
IE862525L (en) 1987-03-25
FR2587720B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-02-10
PT83434A (en) 1986-10-01
SE9102975L (sv) 1993-04-15
IL80073A0 (en) 1986-12-31
NO863803D0 (no) 1986-09-24
GB2181435B (en) 1990-01-10
CN1020752C (zh) 1993-05-19
DE3690508T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-06-23
IT8667730A0 (it) 1986-09-24
HUT42133A (en) 1987-06-29
SE9102974L (sv) 1993-04-15
SE9102975D0 (sv) 1991-10-14
IT1195829B (it) 1988-10-27
NL8602422A (nl) 1987-04-16
YU46753B (sh) 1994-05-10
CN86106632A (zh) 1987-05-13
SE9102976D0 (sv) 1991-10-14
PT83434B (pt) 1988-07-29
FI863848A0 (fi) 1986-09-24
WO1987002038A1 (en) 1987-04-09
DK455486D0 (da) 1986-09-24
ATA256786A (de) 1995-05-15
IL80073A (en) 1995-01-24
FI863848A7 (fi) 1987-03-26

Similar Documents

Publication Publication Date Title
ES2002490A6 (es) Un metodo de preparar un virus recombinante
ES2053413T3 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
ATE183515T1 (de) Zusammensetzungen die die hiv replikation inhibieren
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
DE60037450D1 (de) Funf-helix protein
CL2009002139A1 (es) Peptido sintetico que comprende la secuencia sec id no:6 y sec id no:7 de la proteina gp41 del virus vih con actividad antiretroviral.
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ES2062971T3 (es) Peptidos de la cubierta de htlv iii.
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ES2124532T3 (es) Sistema vector-huesped utilizable en terapia genica.
DK166284C (da) Immunologisk aktivt peptid, der er i stand til at fremkalde immunisering mod malaria, malariamodvirkende immunogent stimulerende middel, der indeholder peptidet, anvendelse af peptidet til fremstilling af et saadant middel, en dna-sekvens, der koder for peptidet, en rekombinant dna-kloningsbaerer, der omfatter dna-sekvensen samt e. coli, der indeholder kloningsbaereren
ES2191663T3 (es) Virus recombinante de la viruela porcina.
DK163683D0 (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykkedna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
DE69535601D1 (de) Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
AR248045A1 (es) Procedimiento para producir un virus de avipox recombinante, un cultivo de celulas eucariotica, una vacuna y para expresar la totalidad o parte de una proteina heterologa, secuencia de transferencia
AR003135A1 (es) Baculovirus recombinante, una vacuna que los contiene, y el uso del mismo para preparar una vacuna util para evitar o disminuir la enfermedad causada porvirus de inmunodeficiencia felina.
FI963717A7 (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
ES2052589T3 (es) Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo.
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
ES2062521T3 (es) Peptidos sinteticos para una vacuna contra hiv-1.
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2006-09-24

FD1A Patent lapsed

Effective date: 20000601